Global Immuno-Oncology Drugs Market Report 2024

Immuno-Oncology Drugs Global Market Report 2024 – By Type (Immune Checkpoint Inhibitors, Immune System Modulators, Other Monoclonal Antibodies, Cancer Vaccines, Others), By Therapeutic Application (Melanoma, Lung Cancer, Blood Cancer, Renal Cell Carcinoma, Bladder Cancer, Other Therapeutic Application), By End-Users (Hospitals, Clinics, Ambulatory Surgical Centers, Others) – Market Size, Trends, And Global Forecast 2024-2033

Immuno-Oncology Drugs Global Market Report 2024

Starting Price : $5000.00 | Pages : 250 | Published : January 2024 | Delivery Time: 2-3 business days | Format : pdf

Need assistance or more information before the purchase?

Enquire Before Buying
Immuno-Oncology Drugs Global Market Report 2024

Proud Members Of

checkslacipN checkaoirsN checkscipN

Immuno-Oncology Drugs Market Definition And Segments

Immuno-oncology drugs refer to a therapy or cancer treatment that employs drugs to either boost or suppress the immune system in order to aid the body's defenses against cancer, infection, and other disorders. It makes use of chemicals produced by the body or in a lab to strengthen the immune system and assist the body in locating and eliminating cancer cells.

The main types of immuno-oncology drugs market are monoclonal antibodies, immune checkpoint inhibitors, immune system modulators, cancer vaccines, and others. Monoclonal antibodies are created by cloning a single white blood cell. Every subsequent antibody generated in this manner may be traced back to a single parent cell. The different therapeutic applications include melanoma, lung cancer, blood cancer, renal cell carcinoma, prostate cancer, bladder cancer, and others and involve various sectors such as hospitals, clinics, ambulatory surgical centers, and cancer research institutes.

The immuno-oncology drugs market covered in this report is segmented –

1) By Type: Immune Checkpoint Inhibitors, Immune System Modulators, Other Monoclonal Antibodies, Cancer Vaccines, Others

2) By Therapeutic Application: Melanoma, Lung Cancer, Blood Cancer, Renal Cell Carcinoma, Bladder Cancer, Other Therapeutic Application

3) By End-Users: Hospitals, Clinics, Ambulatory Surgical Centers, Others

The immuno-oncology drugs market size has grown rapidly in recent years. It will grow from $92.78 billion in 2023 to $105.64 billion in 2024 at a compound annual growth rate (CAGR) of 13.9%. The growth in the historic period can be attributed to rise in the number of cancer cases, strong economic growth in emerging markets, increased healthcare expenditure, and an increase in pharmaceutical R&D expenditure. the market was restrained by high cost of immuno-oncology therapies, low healthcare access, pricing pressures from regulators, high R&D costs, and patent expiration of drugs.

The immuno-oncology drugs market size is expected to see rapid growth in the next few years. It will grow to $175.05 billion in 2028 at a compound annual growth rate (CAGR) of 13.5%. The growth in the forecast period can be attributed to increasing investment in immuno-oncology, rising focus on immunotherapy drugs for cancer treatment, product innovations. Major trends in the forecast period include investing in developing personalized oncology drugs to treat specific patients, focus efforts on the development of next-generation biologics, focus on the development of antibody-drug conjugates, invest in AI solutions, reduce R&D costs and save development time, immune-oncology combination therapies to boost innovation and establish category leadership, and implement car-t therapies to boost innovations and establish category leadership.

Global Surge In Cancer Cases And Its Effect On The Market

The rise in the number of cancer cases across the globe is likely to contribute to the growth of the immuno-oncology drugs market. For instance, in January 2022, according to the American Cancer Society, there will likely be 1.9 million new cancer diagnoses and 609,360 cancer-related deaths in the US, or roughly 1,670 fatalities every day. The four most common types of cancer worldwide are lung, prostate, bowel, and female breast cancer, accounting for 43% of all new cancer cases. The four most common types of cancer worldwide are lung, prostate, bowel, and female breast cancer, accounting for 43% of new cancer cases. Therefore, the rise in cancer incidence rates globally is anticipated to boost demand for the immune-oncology drugs market over the coming years.

Surge In Healthcare Expenditure Propelling The Immuno-Oncology Drugs Market

The increasing healthcare expenditure is expected to propel the growth of the immuno-oncology drugs market. Healthcare expenditure refers to the total amount of money spent by individuals, organizations, or governments on healthcare-related goods and services within a specific period. Increasing healthcare expenditure can potentially boost the development, accessibility, and utilization of immuno-oncology drugs, ultimately improving cancer treatment outcomes and patient access to these innovative therapies. For instance, in 2021, as per the Centers for Medicare & Medicaid Services (CMS), a US-based government agency, U.S. health care spending grew 2.7 percent, reaching $4.3 trillion, or $12,914 per person. Therefore, increasing healthcare expenditure will drive the immuno-oncology drugs market forward.

Major companies operating in the immuno-oncology drugs market report are F. Hoffmann-La Roche Ltd., Merck & Co., Bristol-Myers Squibb Company, Amgen Inc., Johnson & Johnson, AstraZeneca PLC, Eli Lilly and Company, Novartis International AG, Pfizer Inc., Sanofi S.A., Arlak Biotech, Healthkind Labs Pvt. Ltd., SwisscheM Healthcare Pvt.Ltd., Apikos Pharma, Kolaz biotech, CStone Pharma, CARsgen Therapeutics, JW Therapeutics, BeiGene, Takeda Pharmaceuticals, Astellas Pharma Inc., Otsuka Pharmaceutical Co, Ltd., Legend Biotech Co, Zai Lab, Daiichi Pharmaceutical and Sankyo, AQVIDA GmbH, Baxter International Inc., GlaxoSmithKline PLC, Affimed Therapeutics, Autolus Therapeutics, Cellectis, Celyad, GammaDelta Therapeutics, Immunocore, European Medical Center (EMC), Yauza Medical Center, Celon Pharma, Veropharm, Biocad, Selvita, OncoArendi Therapeutics Mabion, Fate Therapeutics, Forty-Seven, Arcus Biosciences, Gritstone Oncology, Rakuten Medical, Rubius Therapeutics, Allogene Therapeutics, Celgene Corporation, Bayer AG, Incyte Corporation, Recepta Biopharma, CSC Pharmaceuticals International, Blanver EN, Sandoz Brazil, Life Pharma, Julphar, NewBridge Pharmaceuticals, Eurolab

The High Cost Of Immunotherapy Drugs

The high cost of immuno-oncology drugs market is a key factor hampering the growth of the market. The immunotherapy drugs cost more than other cancer drugs, and people who need immunotherapy for cancer, are often not able to afford it. High costs associated with drugs are a major issue faced by patients across the globe. The pressure to contain costs and demonstrate value is widespread. In less wealthy countries, the lack of cost-effective drugs has influenced the health conditions of the population and led to a low average life expectancy. Immunotherapy often costs an average annual price of more than $100,000 per patient, and if the value of medical assistance is included, the price would reach $850,000 per patient. Therefore, the high cost of immuno-oncology drugs market is expected to hinder the growth of the immuno-oncology drugs market.

Collaboration In The Immuno-Oncology Drugs Market

Companies in the immuno-oncology drugs market are increasing their product innovation through strategic collaborations. To sustain themselves in the increasingly competitive immuno-oncology drugs market, companies are developing innovative products as well as sharing skills and expertise with other companies. While companies have long collaborated with academic and research institutions in this market by way of partnerships and in- or out-licensing deals, this trend has been increasing over the past few years. For instance, in September 2021, Boehringer Ingelheim, a Germany-based pharmaceutical company and OSE Immunotherapeutic, a France-based biotechnology company announced a collaboration and license agreement to develop a novel checkpoint inhibitor for the treatment of advanced solid tumors.

Immuno-Oncology Product Advancements

Major companies operating in the immuno-oncology drugs market are focusing on product developments, such as Tebentafusp-TEBN, to expand their product portfolio in the field of cancer therapy. Tebentafusp-TEBN is a novel immuno-oncology drug. It is a fusion protein that combines a T-cell receptor (TCR) with an anti-CD3 antibody fragment. This unique construct is designed to target and engage T cells with cancer cells, particularly melanoma, in an effort to activate the immune system's response against cancer. For instance, in January 2022, Immunocore, a UK-based biotechnology company, announced the Food and Drug Administration (FDA) approval for KIMMTRAKR (Tebentafusp-TEBN) for treating HLA-A02:01-positive adult patients with unresectable or metastatic uveal melanoma. KIMMTRAK is a bispecific gp100 peptide-HLA-directed CD3 T cell engager that significantly extends overall survival in a randomized clinical trial, making it the first FDA-approved treatment for this condition.

Sanofi SA Acquired Amunix Pharmaceuticals

In December 2021, Sanofi S.A., a France-based biopharmaceutical and healthcare company, acquired Amunix Pharmaceuticals, Inc., for an amount of $1 billion. Through this acquisition, Sanofi increases its capabilities in the development of innovative medicines for cancer patients, in research and drug discovery of immune-oncology therapeutic candidates, brings these potentially superior and safer treatment candidates to patients by utilizing its expertise and working as a center of excellence together, and increases its oncology pipeline. Amunix Pharmaceuticals, Inc., is a US-based biopharmaceutical company specializing in the discovery and development of novel immuno-oncology drugs.

North America was the largest region in the immuno-oncology drugs market in 2023. The regions covered in the immuno-oncology drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the immuno-oncology drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain

The immuno-oncology drugs market consists of sales of bevacizumab, alectinib, ibrutinib, imatinib, and palbociclib. Values in this market are "factory gate values," that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The immuno-oncology drugs market research report is one of a series of new reports from The Business Research Company that provides immuno-oncology drugs market statistics, including industry global market size, regional shares, competitors with an immuno-oncology drugs market share, detailed immuno-oncology drugs market segments, market trends and opportunities, and any further data you may need to thrive in the immuno-oncology drugs industry. This immuno-oncology drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Immuno-Oncology Drugs Market Report Scope
Report AttributeDetails
Market Size Value In 2024 $105.64 billion
Revenue Forecast In 2033 $175.05 billion
Growth Rate CAGR of 13.5% from 2024 to 2033
Base Year For Estimation 2023
Actual Estimates/Historical Data 2018-2023
Forecast Period 2024 - 2028 - 2033
Market Representation Revenue in USD Billion and CAGR from 2024 to 2033
Segments Covered 1) By Type: Immune Checkpoint Inhibitors, Immune System Modulators, Other Monoclonal Antibodies, Cancer Vaccines, Others
2) By Therapeutic Application: Melanoma, Lung Cancer, Blood Cancer, Renal Cell Carcinoma, Bladder Cancer, Other Therapeutic Application
3) By End-Users: Hospitals, Clinics, Ambulatory Surgical Centers, Others
Regional Scope Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Country Scope Australia; China; India; Indonesia; Japan; South Korea; Bangladesh; Thailand; Vietnam; Malaysia; Singapore; Philippines; Hong Kong; New Zealand; USA; Canada; Mexico; Brazil; Chile; Argentina; Colombia; Peru; France; Germany; UK; Austria; Belgium; Denmark; Finland; Ireland; Italy; Netherlands; Norway; Portugal; Spain; Sweden; Switzerland; Russia; Czech Republic; Poland; Romania; Ukraine; Saudi Arabia; Israel; Iran; Turkey; UAE; Egypt; Nigeria; South Africa
Key Companies Profiled F. Hoffmann-La Roche Ltd.; Merck & Co.; Bristol-Myers Squibb Company; Amgen Inc; Johnson & Johnson; AstraZeneca Plc; Eli Lilly and Company; Novartis International AG; Pfizer Inc.; Sanofi S.A.; Arlak Biotech; Healthkind Labs Pvt. Ltd.; SwisscheM Healthcare Pvt.Ltd; Apikos Pharma; Kolaz biotech; CStone Pharma; CARsgen Therapeutics; JW Therapeutics; BeiGene; Takeda Pharmaceuticals; Astellas Pharma Inc; Otsuka Pharmaceutical Co, Ltd; Legend Biotech Co; Zai Lab; Daiichi Pharmaceutical and Sankyo; AQVIDA GmbH; Baxter International Inc.; GlaxoSmithKline plc; Affimed Therapeutics; Autolus Therapeutics; Cellectis; Celyad; GammaDelta Therapeutics; Immunocore; European Medical Center (EMC); Yauza Medical Center; Celon Pharma; Veropharm; Biocad; Selvita; OncoArendi Therapeutics Mabion; Fate Therapeutics; Forty-Seven; Arcus Biosciences; Gritstone Oncology; Rakuten Medical; Rubius Therapeutics; Allogene Therapeutics; Celgene Corporation; Bayer AG; Incyte Corporation; Recepta Biopharma; CSC Pharmaceuticals International; Blanver EN; Sandoz Brazil; Life Pharma; Julphar; NewBridge Pharmaceuticals; Eurolab
Customization ScopeRequest for Sample
Pricing And Purchase OptionsExplore Purchase Options

    Table Of Contents

    1. Executive Summary

    2. Immuno-Oncology Drugs Market Characteristics

    3. Immuno-Oncology Drugs Market Trends And Strategies

    4. Immuno-Oncology Drugs Market - Macro Economic Scenario

    4.1. Impact Of High Inflation On The Market

    4.2. Ukraine-Russia War Impact On The Market

    4.3. COVID-19 Impact On The Market

    5. Global Immuno-Oncology Drugs Market Size and Growth

    5.1. Global Immuno-Oncology Drugs Market Drivers and Restraints

    5.1.1. Drivers Of The Market

    5.1.2. Restraints Of The Market

    5.2. Global Immuno-Oncology Drugs Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)

    5.3. Global Immuno-Oncology Drugs Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

    6. Immuno-Oncology Drugs Market Segmentation

    6.1. Global Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Monoclonal Antibodies

    Immune Checkpoint Inhibitors

    Immune System Modulators

    Cancer Vaccines

    Other Types

    6.2. Global Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Melanoma

    Lung Cancer

    Blood Cancer

    Renal Cell Carcinoma

    Prostate Cancer

    Bladder Cancer

    Other Therapeutic Applications

    6.3. Global Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Hospitals

    Clinics

    Ambulatory Surgical Centers

    Cancer Research Institutes

    7. Immuno-Oncology Drugs Market Regional And Country Analysis

    7.1. Global Immuno-Oncology Drugs Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    7.2. Global Immuno-Oncology Drugs Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8. Asia-Pacific Immuno-Oncology Drugs Market

    8.1. Asia-Pacific Immuno-Oncology Drugs Market Overview

    Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

    8.2. Asia-Pacific Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8.3. Asia-Pacific Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8.4. Asia-Pacific Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    9. China Immuno-Oncology Drugs Market

    9.1. China Immuno-Oncology Drugs Market Overview

    9.2. China Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    9.3. China Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    9.4. China Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    10. India Immuno-Oncology Drugs Market

    10.1. India Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    10.2. India Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    10.3. India Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11. Japan Immuno-Oncology Drugs Market

    11.1. Japan Immuno-Oncology Drugs Market Overview

    11.2. Japan Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11.3. Japan Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11.4. Japan Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12. Australia Immuno-Oncology Drugs Market

    12.1. Australia Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12.2. Australia Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12.3. Australia Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13. Indonesia Immuno-Oncology Drugs Market

    13.1. Indonesia Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13.2. Indonesia Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13.3. Indonesia Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14. South Korea Immuno-Oncology Drugs Market

    14.1. South Korea Immuno-Oncology Drugs Market Overview

    14.2. South Korea Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14.3. South Korea Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14.4. South Korea Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15. Western Europe Immuno-Oncology Drugs Market

    15.1. Western Europe Immuno-Oncology Drugs Market Overview

    15.2. Western Europe Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15.3. Western Europe Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15.4. Western Europe Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16. UK Immuno-Oncology Drugs Market

    16.1. UK Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16.2. UK Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16.3. UK Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17. Germany Immuno-Oncology Drugs Market

    17.1. Germany Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17.2. Germany Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17.3. Germany Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18. France Immuno-Oncology Drugs Market

    18.1. France Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18.2. France Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18.3. France Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19. Italy Immuno-Oncology Drugs Market

    19.1. Italy Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19.2. Italy Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19.3. Italy Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20. Spain Immuno-Oncology Drugs Market

    20.1. Spain Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20.2. Spain Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20.3. Spain Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21. Eastern Europe Immuno-Oncology Drugs Market

    21.1. Eastern Europe Immuno-Oncology Drugs Market Overview

    21.2. Eastern Europe Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21.3. Eastern Europe Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21.4. Eastern Europe Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22. Russia Immuno-Oncology Drugs Market

    22.1. Russia Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22.2. Russia Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22.3. Russia Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23. North America Immuno-Oncology Drugs Market

    23.1. North America Immuno-Oncology Drugs Market Overview

    23.2. North America Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23.3. North America Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23.4. North America Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24. USA Immuno-Oncology Drugs Market

    24.1. USA Immuno-Oncology Drugs Market Overview

    24.2. USA Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24.3. USA Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24.4. USA Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25. Canada Immuno-Oncology Drugs Market

    25.1. Canada Immuno-Oncology Drugs Market Overview

    25.2. Canada Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25.3. Canada Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25.4. Canada Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26. South America Immuno-Oncology Drugs Market

    26.1. South America Immuno-Oncology Drugs Market Overview

    26.2. South America Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26.3. South America Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26.4. South America Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27. Brazil Immuno-Oncology Drugs Market

    27.1. Brazil Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27.2. Brazil Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27.3. Brazil Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28. Middle East Immuno-Oncology Drugs Market

    28.1. Middle East Immuno-Oncology Drugs Market Overview

    28.2. Middle East Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28.3. Middle East Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28.4. Middle East Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29. Africa Immuno-Oncology Drugs Market

    29.1. Africa Immuno-Oncology Drugs Market Overview

    29.2. Africa Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29.3. Africa Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29.4. Africa Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    30. Immuno-Oncology Drugs Market Competitive Landscape And Company Profiles

    30.1. Immuno-Oncology Drugs Market Competitive Landscape

    30.2. Immuno-Oncology Drugs Market Company Profiles

    30.2.1. F. Hoffmann-La Roche Ltd.

    30.2.1.1. Overview

    30.2.1.2. Products and Services

    30.2.1.3. Strategy

    30.2.1.4. Financial Performance

    30.2.2. Merck & Co.

    30.2.2.1. Overview

    30.2.2.2. Products and Services

    30.2.2.3. Strategy

    30.2.2.4. Financial Performance

    30.2.3. Bristol-Myers Squibb Company

    30.2.3.1. Overview

    30.2.3.2. Products and Services

    30.2.3.3. Strategy

    30.2.3.4. Financial Performance

    30.2.4. Amgen Inc

    30.2.4.1. Overview

    30.2.4.2. Products and Services

    30.2.4.3. Strategy

    30.2.4.4. Financial Performance

    30.2.5. Johnson & Johnson

    30.2.5.1. Overview

    30.2.5.2. Products and Services

    30.2.5.3. Strategy

    30.2.5.4. Financial Performance

    31. Immuno-Oncology Drugs Market Other Major And Innovative Companies

    31.1. AstraZeneca Plc

    31.2. Eli Lilly and Company

    31.3. Novartis International AG

    31.4. Pfizer Inc.

    31.5. Sanofi S.A.

    31.6. Arlak Biotech

    31.7. Healthkind Labs Pvt. Ltd.

    31.8. SwisscheM Healthcare Pvt.Ltd

    31.9. Apikos Pharma

    31.10. Kolaz biotech

    31.11. CStone Pharma

    31.12. CARsgen Therapeutics

    31.13. JW Therapeutics

    31.14. BeiGene

    31.15. Takeda Pharmaceuticals

    32. Global Immuno-Oncology Drugs Market Competitive Benchmarking

    33. Global Immuno-Oncology Drugs Market Competitive Dashboard

    34. Key Mergers And Acquisitions In The Immuno-Oncology Drugs Market

    35. Immuno-Oncology Drugs Market Future Outlook and Potential Analysis

    35.1 Immuno-Oncology Drugs Market In 2028 - Countries Offering Most New Opportunities

    35.2 Immuno-Oncology Drugs Market In 2028 - Segments Offering Most New Opportunities

    35.3 Immuno-Oncology Drugs Market In 2028 - Growth Strategies

    35.3.1 Market Trend Based Strategies

    35.3.2 Competitor Strategies

    36. Appendix

    36.1. Abbreviations

    36.2. Currencies

    36.3. Historic And Forecast Inflation Rates

    36.4. Research Inquiries

    36.5. The Business Research Company

    36.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2018-2023, $ Billion
  • Table 2: Global Forecast Market Growth, 2023-2028F, 2033F, $ Billion
  • Table 3: Global Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 4: Global Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 5: Global Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 6: Global Immuno-Oncology Drugs Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 7: Global Immuno-Oncology Drugs Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 8: Asia-Pacific, Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 9: Asia-Pacific, Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 10: Asia-Pacific, Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 11: China, Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 12: China, Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 13: China, Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 14: India, Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 15: India, Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 16: India, Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 17: Japan, Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 18: Japan, Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 19: Japan, Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 20: Australia, Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 21: Australia, Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 22: Australia, Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 23: Indonesia, Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 24: Indonesia, Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 25: Indonesia, Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 26: South Korea, Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 27: South Korea, Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 28: South Korea, Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 29: Western Europe, Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 30: Western Europe, Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 31: Western Europe, Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 32: UK, Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 33: UK, Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 34: UK, Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 35: Germany, Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 36: Germany, Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 37: Germany, Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 38: France, Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 39: France, Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 40: France, Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 41: Italy, Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 42: Italy, Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 43: Italy, Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 44: Spain, Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 45: Spain, Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 46: Spain, Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 47: Eastern Europe, Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 48: Eastern Europe, Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 49: Eastern Europe, Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 50: Russia, Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 51: Russia, Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 52: Russia, Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 53: North America, Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 54: North America, Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 55: North America, Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 56: USA, Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 57: USA, Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 58: USA, Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 59: Canada, Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 60: Canada, Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 61: Canada, Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 62: South America, Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 63: South America, Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 64: South America, Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 65: Brazil, Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 66: Brazil, Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 67: Brazil, Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 68: Middle East, Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 69: Middle East, Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 70: Middle East, Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 71: Africa, Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 72: Africa, Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 73: Africa, Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 74: F. Hoffmann-La Roche Ltd. Financial Performance
  • Table 75: Merck & Co. Financial Performance
  • Table 76: Bristol-Myers Squibb Company Financial Performance
  • Table 77: Amgen Inc Financial Performance
  • Table 78: Johnson & Johnson Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2018-2023, $ Billion
  • Figure 2: Global Forecast Market Growth, 2023-2028F, 2033F, $ Billion
  • Figure 3: Global Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 4: Global Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 5: Global Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 6: Global Immuno-Oncology Drugs Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 7: Global Immuno-Oncology Drugs Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 8: Asia-Pacific, Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 9: Asia-Pacific, Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 10: Asia-Pacific, Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 11: China, Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 12: China, Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 13: China, Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 14: India, Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 15: India, Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 16: India, Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 17: Japan, Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 18: Japan, Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 19: Japan, Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 20: Australia, Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 21: Australia, Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 22: Australia, Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 23: Indonesia, Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 24: Indonesia, Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 25: Indonesia, Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 26: South Korea, Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 27: South Korea, Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 28: South Korea, Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 29: Western Europe, Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 30: Western Europe, Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 31: Western Europe, Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 32: UK, Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 33: UK, Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 34: UK, Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 35: Germany, Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 36: Germany, Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 37: Germany, Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 38: France, Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 39: France, Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 40: France, Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 41: Italy, Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 42: Italy, Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 43: Italy, Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 44: Spain, Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 45: Spain, Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 46: Spain, Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 47: Eastern Europe, Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 48: Eastern Europe, Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 49: Eastern Europe, Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 50: Russia, Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 51: Russia, Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 52: Russia, Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 53: North America, Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 54: North America, Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 55: North America, Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 56: USA, Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 57: USA, Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 58: USA, Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 59: Canada, Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 60: Canada, Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 61: Canada, Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 62: South America, Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 63: South America, Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 64: South America, Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 65: Brazil, Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 66: Brazil, Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 67: Brazil, Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 68: Middle East, Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 69: Middle East, Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 70: Middle East, Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 71: Africa, Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 72: Africa, Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 73: Africa, Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 74: F. Hoffmann-La Roche Ltd. Financial Performance
  • Figure 75: Merck & Co. Financial Performance
  • Figure 76: Bristol-Myers Squibb Company Financial Performance
  • Figure 77: Amgen Inc Financial Performance
  • Figure 78: Johnson & Johnson Financial Performance
View Report
View Report
View Report
View Report
View Report
View Report
View Report

Frequently Asked Questions

What is the definition of the immuno-oncology drugs market?

Immuno-oncology drugs refer to a therapy or cancer treatment that employs drugs to either boost or suppress the immune system in order to aid the body's defenses against cancer, infection, and other disorders. It makes use of chemicals produced by the body or in a lab to strengthen the immune system and assist the body in locating and eliminating cancer cells. For further insights on the immuno-oncology drugs market, request a sample here

How will the immuno-oncology drugs market drivers and restraints affect the immuno-oncology drugs market dynamics? What forces will shape the immuno-oncology drugs industry going forward?

The immuno-oncology drugs market major growth driver - Global Surge In Cancer Cases And Its Effect On The Market. For further insights on the immuno-oncology drugs market, request a sample here

What is the forecast market size or the forecast market value of the immuno-oncology drugs market?

The immuno-oncology drugs market size has grown rapidly in recent years. It will grow from $92.78 billion in 2023 to $105.64 billion in 2024 at a compound annual growth rate (CAGR) of 13.9%. The growth in the historic period can be attributed to rise in the number of cancer cases, strong economic growth in emerging markets, increased healthcare expenditure, and an increase in pharmaceutical r&d expenditure. the market was restrained by high cost of immuno-oncology therapies, low healthcare access, pricing pressures from regulators, high r&d costs, and patent expiration of drugs.. The immuno-oncology drugs market size is expected to see rapid growth in the next few years. It will grow to $175.05 billion in 2028 at a compound annual growth rate (CAGR) of 13.5%. The growth in the forecast period can be attributed to increasing investment in immuno-oncology, rising focus on immunotherapy drugs for cancer treatment, product innovations through strategic collaborations and increasing geriatric population are expected to drive the market. . Major trends in the forecast period include companies should develop microneedle injector-based drugs to increase the bioavailability and eliminate side effects of the subcutaneous route, consider investing in developing personalized oncology drugs to treat specific patients, consider investing in acquisitions to increase market shares and expand their product portfolio offerings, focus efforts on the development of next-generation biologics to increase revenue and market share, focus on the development of antibody-drug conjugates to manufacture medicines for cancer treatment, invest in ai solutions, reduce r&d costs and save development time, invest in 3d printing devices to test new oncology drugs, opt for immune-oncology combination therapies to boost innovation and establish category leadership, and implement car-t therapies to boost innovations and establish category leadership.. For further insights on the immuno-oncology drugs market, request a sample here

How is the immuno-oncology drugs market segmented?

The immuno-oncology drugs market is segmented
1) By Type: Immune Checkpoint Inhibitors, Immune System Modulators, Other Monoclonal Antibodies, Cancer Vaccines, Others
2) By Therapeutic Application: Melanoma, Lung Cancer, Blood Cancer, Renal Cell Carcinoma, Bladder Cancer, Other Therapeutic Application
3) By End-Users: Hospitals, Clinics, Ambulatory Surgical Centers, OthersFor further insights on the immuno-oncology drugs market,
request a sample here

Which region has the largest share of the immuno-oncology drugs market? What are the other regions covered in the report?

North America was the largest region in the immuno-oncology drugs market in 2023. The regions covered in the immuno-oncology drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa For further insights on the immuno-oncology drugs market, request a sample here.

Who are the major players in the immuno-oncology drugs market?

Major companies operating in the immuno-oncology drugs market report are F. Hoffmann-La Roche Ltd., Merck & Co., Bristol-Myers Squibb Company, Amgen Inc, Johnson & Johnson, AstraZeneca Plc, Eli Lilly and Company, Novartis International AG, Pfizer Inc., Sanofi S.A., Arlak Biotech, Healthkind Labs Pvt. Ltd., SwisscheM Healthcare Pvt.Ltd, Apikos Pharma, Kolaz biotech, CStone Pharma, CARsgen Therapeutics, JW Therapeutics, BeiGene, Takeda Pharmaceuticals, Astellas Pharma Inc, Otsuka Pharmaceutical Co, Ltd, Legend Biotech Co, Zai Lab, Daiichi Pharmaceutical and Sankyo, AQVIDA GmbH, Baxter International Inc., GlaxoSmithKline plc, Affimed Therapeutics, Autolus Therapeutics, Cellectis, Celyad, GammaDelta Therapeutics, Immunocore, European Medical Center (EMC), Yauza Medical Center, Celon Pharma, Veropharm, Biocad, Selvita, OncoArendi Therapeutics Mabion, Fate Therapeutics, Forty-Seven, Arcus Biosciences, Gritstone Oncology, Rakuten Medical, Rubius Therapeutics, Allogene Therapeutics, Celgene Corporation, Bayer AG, Incyte Corporation, Recepta Biopharma, CSC Pharmaceuticals International, Blanver EN, Sandoz Brazil, Life Pharma, Julphar, NewBridge Pharmaceuticals, Eurolab For further insights on the immuno-oncology drugs market, request a sample here.

What are the key trends in the immuno-oncology drugs market?

Major trend in the immuno-oncology drugs market - Collaboration In The Immuno-Oncology Drugs Market. For further insights on the immuno-oncology drugs market, request a sample here.

What are the major opportunities in the immuno-oncology drugs market? What are the strategies for the immuno-oncology drugs market?

For detailed insights on the major opportunities and strategies in the immuno-oncology drugs market, request a sample here.

How does the immuno-oncology drugs market relate to the overall economy and other similar markets?

For detailed insights on immuno-oncology drugs market's relation to the overall economy and other similar markets, request a sample here.

What are the latest mergers and acquisitions in the immuno-oncology drugs industry?

For detailed insights on the mergers and acquisitions in the immuno-oncology drugs industry, request a sample here.

What are the key dynamics influencing the immuno-oncology drugs market growth? SWOT analysis of the immuno-oncology drugs market.

For detailed insights on the key dynamics influencing the immuno-oncology drugs market growth and SWOT analysis of the immuno-oncology drugs industry, request a sample here.